125 related articles for article (PubMed ID: 38659368)
1. Dual T cell receptor/chimeric antigen receptor engineered NK-92 cells targeting the HPV16 E6 oncoprotein and the tumor-associated antigen L1CAM exhibit enhanced cytotoxicity and specificity against tumor cells.
Quiros-Fernandez I; Libório-Ramos S; Leifert L; Schönfelder B; Vlodavsky I; Cid-Arregui A
J Med Virol; 2024 May; 96(5):e29630. PubMed ID: 38659368
[TBL] [Abstract][Full Text] [Related]
2. A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7.
Poorebrahim M; Quiros-Fernandez I; Marmé F; Burdach SE; Cid-Arregui A
Cancer Lett; 2023 Jul; 566():216242. PubMed ID: 37217069
[TBL] [Abstract][Full Text] [Related]
3. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6.
Draper LM; Kwong ML; Gros A; Stevanović S; Tran E; Kerkar S; Raffeld M; Rosenberg SA; Hinrichs CS
Clin Cancer Res; 2015 Oct; 21(19):4431-9. PubMed ID: 26429982
[TBL] [Abstract][Full Text] [Related]
4. Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer.
Scholten KB; Turksma AW; Ruizendaal JJ; van den Hende M; van der Burg SH; Heemskerk MH; Meijer CJ; Hooijberg E
J Transl Med; 2011 Sep; 9():147. PubMed ID: 21892941
[TBL] [Abstract][Full Text] [Related]
5. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
[TBL] [Abstract][Full Text] [Related]
6. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
7. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
9. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
[TBL] [Abstract][Full Text] [Related]
10. Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable.
Wang X; Moscicki AB; Tsang L; Brockman A; Nakagawa M
Clin Vaccine Immunol; 2008 Jun; 15(6):937-45. PubMed ID: 18448624
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer.
Zehbe I; Kaufmann AM; Schmidt M; Hohn H; Maeurer MJ
J Immunother; 2007; 30(5):523-32. PubMed ID: 17589293
[TBL] [Abstract][Full Text] [Related]
12. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
13. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
14. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
[TBL] [Abstract][Full Text] [Related]
15. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
[TBL] [Abstract][Full Text] [Related]
16. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
Morishima S; Akatsuka Y; Nawa A; Kondo E; Kiyono T; Torikai H; Nakanishi T; Ito Y; Tsujimura K; Iwata K; Ito K; Kodera Y; Morishima Y; Kuzushima K; Takahashi T
Int J Cancer; 2007 Feb; 120(3):594-604. PubMed ID: 17096336
[TBL] [Abstract][Full Text] [Related]
17. HPV16 E6 29-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function.
Thomas KJ; Smith KL; Youde SJ; Evans M; Fiander AN; Borysiewicz LK; Man S
Int J Cancer; 2008 Jun; 122(12):2791-9. PubMed ID: 18366058
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.
Ramos CA; Narala N; Vyas GM; Leen AM; Gerdemann U; Sturgis EM; Anderson ML; Savoldo B; Heslop HE; Brenner MK; Rooney CM
J Immunother; 2013 Jan; 36(1):66-76. PubMed ID: 23211628
[TBL] [Abstract][Full Text] [Related]
19. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8
Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y
Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.
Nilges K; Höhn H; Pilch H; Neukirch C; Freitag K; Talbot PJ; Maeurer MJ
J Virol; 2003 May; 77(9):5464-74. PubMed ID: 12692247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
